Search Results 271-280 of 17346 for GLP-1 secretion
PTT-936, an Alpha Kinase 1 (ALPK1) Activator, Alone or in Combination with Anti-PD-1/L1 in Patients with Locally Advanced or Metastatic Solid Tumors. Print ...
The purpose of this study is to evaluate molecular markers which might be a predictor of pancreatic cancer or precancer by analyzing the secretions (fluid) from ...
A Phase 1 Dose Escalation and Expansion Study of TGR-1202 + Ruxolitinib in Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (PPV-MF) ...
Participation eligibility · Concurrent use of any non-insulin glucose-lowering agent other than metformin (including GLP-1 agonists, Symlin, DPP-4 inhibitors, ...
Mayo Clinic researchers have developed a genetic test that can help predict how people will respond to weight loss medications such as GLP-1s. ... 1 · 2 · 3 · 4 ...
Mayo Clinic researchers have developed a genetic test that can help predict how people will respond to weight loss medications such as GLP-1s. Latest ...
The purpose of this study is to assess the safety and tolerability of midodrine in patients with Hepatopulmonary Syndrome (HPS). Participation eligibility.
Amyloid formation in type 2 diabetes and regulation of growth hormone gene expression; Autoimmune thyroid disease; Bone metabolism; Calcium in atherogenesis ...
1. Currently taking 2 anti-hypertensive medications (NOTE: no ... Polycystic kidney disease. 12. Diabetes treated with SGLT2 inhibitor and/or GLP-1 agonist
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your donation powers the future of medicine and helps save lives.